; (B) to increase public awareness of rare kidney diseases, particularly in rural and underserved communities; and (C) to develop resources for clinical research into, training in, and demonstration of diagnostic, prevention, control, and treatment methods for, rare kidney diseases. (3) Policies A cooperative agreement or grant under paragraph (1) shall be entered into in accordance with policies established by the Director of the National Institutes of Health. (b) Coordination with other institutes The Director of the Institute shall coordinate the activities under this section with similar activities that are related to rare kidney disease and conducted by other national research institutes, centers, and agencies of the National Institutes of Health and by the Food and Drug Administration. (c) Use of funds An entity that enters into a cooperative agreement or receives a grant under subsection (a) may use funds received through such agreement or grant— (1) to cover patient care costs required to conduct research described in subsection (a)(2)(A); (2) to provide, for the purpose described in subsection (a)(2)(B)— (A) clinical training and continuing education for health professionals and related personnel with respect to rare kidney diseases; and (B) information programs for the public, with respect to rare kidney diseases; and (3) to provide, for the purpose described in subsection (a)(2)(B)— (A) for education of members of the public, particularly through outreach to rural and underserved communities, on the diagnosis (including through routine urinalysis and through genetic testing), prevention, control, and treatment of rare kidney diseases